Ratio Therapeutics closed a $70M Series C to advance its ATLAS trial for targeted radiotherapeutics and expand manufacturing capabilities.
- Amount
- $70M
- Stage
- Series C
- Announced
- 31 July 2026
- Investors
- Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group
- Use of funds
- Advance the ATLAS study of [Ac-225]RTX-2358 in sarcomas, move next-generation RLT candidate into clinic, and expand manufacturing infrastructure.
- Total raised
- $240M to date
- Checked
- Amount and date checked against the press source